Key statistics
As of last trade Verrica Pharmaceuticals Inc (VRCA:NMQ) traded at 1.89, 2.16% above its 52-week low of 1.85, set on Sep 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.97 |
---|---|
High | 2.01 |
Low | 1.88 |
Bid | 1.89 |
Offer | 1.90 |
Previous close | 1.97 |
Average volume | 651.27k |
---|---|
Shares outstanding | 42.67m |
Free float | 20.95m |
P/E (TTM) | -- |
Market cap | 84.06m USD |
EPS (TTM) | -1.88 USD |
Data delayed at least 15 minutes, as of Sep 16 2024 19:57 BST.
More ▼
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
- Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
More ▼